Advertisement


Stuart J. Wong, MD, on Adjuvant Regimen in Resected HNSCC

2025 ASCO Annual Meeting

Advertisement

Stuart J. Wong, MD, of the Medical College of Wisconsin and Plenary discussant, reviews findings from the phase III NIVOPOSTOP randomized trial, which investigated the adjuvant use of nivolumab added to radiochemotherapy for patients with resected head and neck squamous cell carcinoma who are at high risk of relapse (LBA2). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We have been treating resectable head and neck cancer the same for two decades. It has been defined by a couple of clinical trials, an EORTC trial and RTOG trial examining patients for high-risk resected head and neck cancer where patients were randomized to either radiation alone or radiation plus cisplatin. That study was positive and that's how we've been treating patients for two decades—radiation plus high-dose intermittent cisplatin. There have been many attempts to try to improve upon this over the years and probably the biggest area of research has been with radiation, including immunotherapy to that mixture. There have been maybe about six large randomized trials that have combined radiation and immunotherapy and all of those were unfortunately negative. And then this year we had the NIVOPOSTOP trial. So this was a study that enrolled nearly 700 patients and patients were randomized to the standard treatment of radiation-cisplatin versus radiation, cisplatin, and nivolumab. So this study had a primary endpoint of disease-free survival and it was positive. So this is very exciting. From what we can tell, this is a very well-conducted study. The control arm performed very well. It really checks all the boxes for a phase three randomized trial in terms of what we look for—a well-conducted study of interest. This study had an examination of PD-L1 expression. And unlike some of the previous studies, there's a real strong signal that the PD-L1 positive patients had a really strong correlation with clinical outcome. And this probably is the feature that maybe was the difference between this study being positive versus previous generations of studies that were negative. So what does this mean in terms of patient care? Well, we still need more information from this study. There needs to be mature overall survival data. We're looking for other information about maybe granular detail about the PD-L1 positive patients and subgroups. Perhaps one of the biggest things that I think will have an impact on how we integrate this treatment into clinical practice is another big study that was presented this year, and it's called the KEYNOTE-689 study. So this study was a little bit different. Patients got neoadjuvant pembrolizumab followed by surgery, followed by adjuvant pembrolizumab and combined modality therapy. And this study was also positive. So the big difference between these two studies—the KEYNOTE-689 study was neoadjuvant, the NIVOPOSTOP study was purely adjuvant—and the patterns of failure were really different in the studies. The NIVOPOSTOP study was primarily an improvement of locoregional control, and the KEYNOTE-689 study was primarily an improvement in distant metastatic disease. Very confusing. We think we have some idea about why that may be, but this will definitely come into discussion if both of these treatments come into practice.

Related Videos

CNS Cancers

Manmeet Singh Ahluwalia, MD, MBA, FASCO, on Liquid Biopsy in Glioblastoma

Manmeet Singh Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute, Baptist Health South Florida, discusses the ongoing LIBERATE trial, which is evaluating safety and technical efficacy of transcranial MR-guided microbubble-enhanced transcranial focused ultrasound for increasing blood circulating tumor and cell-free DNA levels in adults with glioblastoma (Abstract TPS2094). 

Lung Cancer

Jamie E. Chaft, MD, FASCO, on Resectable EGFR-Mutated NSCLC: NeoADAURA Results

Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, reviews results of the NeoADAURA trial, which looked at neoadjuvant osimertinib with or without chemotherapy vs chemotherapy alone in patients with resectable EGFR-mutated non–small cell lung cancer (NSCLC) (Abstract 8001). 

Breast Cancer

Giuseppe Curigliano, MD, PhD, on Patient-Reported Outcomes From EMBER-3

Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, IRCCS, University of Milano, discusses patient-reported outcomes from the phase III EMBER-3 trial, which investigated treatment with imlunestrant, investigator’s choice of standard endocrine therapy, or imlunestrant plus abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer (Abstract 1001).  

Leukemia

Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, on CLL/SLL: First-Line Zanubrutinib Monotherapy in Patients With del(17p)

Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, of Alfred Hospital and Monash University, reviews results from the 5-year follow-up of arm C of the SEQUOIA trial of treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7011). 

Breast Cancer

Nicholas C. Turner, MD, PhD, on Treating Emergent ESR1 Mutations in Advanced Breast Cancer

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents findings from the phase III, double-blind ctDNA-guided SERENA-6 trial, which evaluated the combination of camizestrant plus a CDK4/6 inhibitor to treat emergent ESR1 mutations during first-line endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer (LBA4). 

Advertisement

Advertisement




Advertisement